TOLREMO therapeutics AG

TOLREMO’s drug candidates aim to complement standard cancer therapies to offer better response rates, longer survival and an improved quality of life. In addition to combination therapies, we investigate our drug candidates for having efficacy as stand-alone agents in cancer indications of defined transcriptomes.

TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of resistance-preventing precision therapies to patients with cancer. Our drug development programs are supported by novel transcriptome-based bioinformatics strategies to guide preclinical translation and clinical development.

TOLREMO’s drug resistance platform is enabled by deep knowledge of assay development for non-mutational drug resistance, phenotypic and biochemical high-throughput screening, complex image analysis algorithms, medicinal chemistry, structure-based drug design, bioinformatics, and unique preclinical models of drug resistance. These capabilities fuel our drug discovery engine and build a strong platform to identify novel drug resistance regulators and develop small molecule therapies against these promising drug targets.

TOLREMO is a privately held Swiss biotechnology company established in 2017 as a spin-off of ETH Zurich, one of the leading science and technology universities in the world. TOLREMO is now headquartered in greater Basel, a European biotech-hub and home to several multi-national pharma companies.